A5038521422- Systemic Lupus Erythematosus Research
- Autoimmune and Inflammatory Disorders Research
- Adolescent and Pediatric Healthcare
- Renal Diseases and Glomerulopathies
- Atherosclerosis and Cardiovascular Diseases
- Childhood Cancer Survivors' Quality of Life
- Liver Diseases and Immunity
- Rheumatoid Arthritis Research and Therapies
- T-cell and B-cell Immunology
- Diabetes and associated disorders
- Lipid metabolism and disorders
- Pregnancy and Medication Impact
- Kawasaki Disease and Coronary Complications
- Complement system in diseases
- Immunodeficiency and Autoimmune Disorders
- Acute Lymphoblastic Leukemia research
- Inflammasome and immune disorders
- Inflammatory Myopathies and Dermatomyositis
- Eosinophilic Esophagitis
- Monoclonal and Polyclonal Antibodies Research
- Parvovirus B19 Infection Studies
- Vasculitis and related conditions
- Streptococcal Infections and Treatments
- Urticaria and Related Conditions
- Ocular Diseases and Behçet’s Syndrome
Nationwide Children's Hospital
2015-2024
The Ohio State University
2014-2024
Columbus Oncology and Hematology Associates
2022
Penn State Milton S. Hershey Medical Center
2022
National Institute on Minority Health and Health Disparities
2022
University of Wisconsin–Madison
2022
Center for Rheumatology
2005-2022
American College of Rheumatology
2018-2021
Amgen (United States)
2021
The Ohio State University Wexner Medical Center
2012-2020
To formulate consensus treatment plans (CTPs) for induction therapy of newly diagnosed proliferative lupus nephritis (LN) in juvenile systemic erythematosus (SLE).A structured formation process was employed by the members Childhood Arthritis and Rheumatology Research Alliance after considering existing medical evidence current approaches.After an initial Delphi survey (response rate = 70%), a 2-day conference, 2 followup surveys rates 63-79%), achieved limited set CTPs addressing LN. These...
Statins reduce atherosclerosis and cardiovascular morbidity in the general population, but their efficacy safety children adolescents with systemic lupus erythematosus (SLE) are unknown. This study was undertaken to determine 3-year of atorvastatin preventing subclinical progression pediatric-onset SLE.
To evaluate risk factors for subclinical atherosclerosis in a population of patients with pediatric systemic lupus erythematosus (SLE).In prospective multicenter study, cohort 221 underwent baseline measurements carotid intima-media thickness (CIMT) as part the Atherosclerosis Prevention Pediatric Lupus Erythematosus (APPLE) trial. SLE disease measures, medications, and traditional were assessed. A standardized protocol was used to assess bilateral common arteries mean maximal IMT 12...
Transition from pediatric to adult health care is a vulnerable period for adolescents and young adults. Challenges include paucity of validated measures assess patients' transition readiness. We evaluated the Readiness Assessment Questionnaire (TRAQ) in adults with rheumatic, gastrointestinal, endocrine disorders. examined whether baseline TRAQ scores other demographic variables predicted over three year follow up period. In this descriptive study at single institution, eighty-nine academic...
Objective Participants in the Atherosclerosis Prevention Paediatric Lupus Erythematosus (APPLE) trial were randomised to placebo or atorvastatin for 36 months. The primary endpoint, reduced carotid intima medial thickness (CIMT) progression, was not met but atorvastatin-treated participants showed a trend of slower CIMT progression. Post-hoc analyses performed assess subgroup benefit from therapy. Methods Subgroups prespecified and defined by age (> ≤15.5 years), systemic lupus...
Noninvasive estimation of the degree inflammation seen on kidney biopsy with lupus nephritis (LN) remains difficult. The objective this study was to develop a Renal Activity Index for Lupus (RAIL) that, based solely laboratory measures, accurately reflects histologic LN activity.We assayed traditional tests and 16 urine biomarkers (UBMs) in children (n = 47) at time biopsy. Histologic activity measured by National Institutes Health index (NIH-AI) tubulointerstitial (TIAI). High LN-activity...
Transition from pediatric to adult care can be a challenging process which leaves young people vulnerable interruptions of and worsening disease status. Efforts improve transition processes outcomes have included development individualized plans, creation clinics, utilization coordinators. Few interventions assessed quantitatively.We outcome satisfaction social worker-centered program in rheumatology clinic. The worker met with patients who were 16 years or older their families, provided...
People often laugh about being "no good at math." Unrecognized, however, is that one-third of American adults are likely too innumerate to operate effectively in financial and health environments. Two numeric competencies conceivably matter-objective numeracy (ability "run the numbers" correctly; like literacy but with numbers) self-efficacy (confidence provides engagement persistence tasks). We reasoned, attaining objective numeracy's benefits should depend on confidence. Specifically,...
Objective. To assess North American pediatric rheumatology providers’ perspectives on practices, barriers, and opportunities concerning the transition from pediatric-centered to adult-centered care. Methods. Childhood Arthritis Rheumatology Research Alliance (CARRA) members completed a 25-item survey assessing current policy awareness, transitional care barriers needs. Results were compared Academy of Pediatrics (AAP) 2008 Results. Over half (158/288, 55%) CARRA survey. Fewer than 10% are...
Recent studies implicate innate immunity to systemic lupus erythematosus (SLE) pathogenesis. Toll-like receptor (TLR)8 is estrogen-regulated and binds viral ssRNA stimulate immune responses, but recent work indicates that microRNA (miR)-21 within extracellular vesicles (EVs) can also trigger this receptor. Our objective was examine TLR8 expression/activation better understand sex-biased responses involving in SLE. data identify an estrogen response element promotes STAT1 expression...
Objective. To delineate urine biomarkers that forecast response to therapy of lupus nephritis (LN). Methods. Starting from the time kidney biopsy, patients with childhood-onset systemic erythematosus who were diagnosed LN studied serially. Levels 15 measured in random spot samples, including adiponectin, α-1-acid glycoprotein (AGP), ceruloplasmin, hemopexin, hepcidin, injury molecule 1, monocyte chemotactic protein-1, lipocalin-like prostaglandin D synthase (LPGDS), transforming growth...
Objective Patients with juvenile‐onset systemic lupus erythematosus (JSLE) have increased atherosclerosis risk. This study investigated novel progression biomarkers in the Atherosclerosis Prevention Pediatric Lupus Erythematosus (APPLE) trial, largest investigator‐led randomized control trial of atorvastatin versus placebo for JSLE, using carotid intima‐media thickness (CIMT) as primary outcome. Methods Unsupervised clustering baseline CIMT and over 36 months was used to stratify patients...
Objective To describe the frequency and types of disease damage occurring with childhood‐onset systemic lupus erythematosus (SLE) as measured by 41‐item Systemic Lupus International Collaborating Clinics/American College Rheumatology Damage Index (SDI), to assess SDI's ability reflect severity. Methods Information for SDI was prospectively collected from 1,048 SLE patients. For a subset 559 patients, physician‐rated severity visual analog scale (MD VAS damage) also available. Frequency items...
Idiopathic inflammatory myopathies (IIM) are a group of autoimmune diseases characterised by myositis-related autoantibodies plus infiltration leucocytes into muscles and/or the skin, leading to destruction blood vessels and muscle fibres, chronic weakness fatigue. While complement-mediated capillary endothelia is implicated in paediatric adult dermatomyositis, complex diversity complement
PV159 / #51 Poster Topic: AS18 - Pediatric SLE Background/Purpose Childhood-onset systemic lupus erythematosus (cSLE) is associated with increased cardiovascular disease risk (CVD risk) starting early in life. As a consequence, 4% of children and young people (CYP) cSLE recruited to large UK study experienced at least 1 CVD-event 2 years post diagnosis, median age 16 years. The APPLE trial, interventional clinical trial cSLE, evaluated the efficacy atorvastatin decreasing atherosclerosis...